Education
About Us
Working with TipRanks
Follow Us
Olema Pharmaceuticals (OLMA)
NASDAQ:OLMA
OLMA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.86 - $13.93
Previous CloseN/A
Volume1.27M
Average Volume (3M)586.17K
Market Cap
$367.42M
Enterprise Value-$70.36M
Total Cash (Recent Filing)$392.71M
Total Debt (Recent Filing)$1.15M
Price to Earnings (P/E)―
Beta1.81
Next Earnings
Aug 12, 2025EPS Estimate
-0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding68,421,280
10 Day Avg. Volume531,994
30 Day Avg. Volume586,173
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.19
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit748.47
Enterprise Value/Ebitda0.49
Forecast
1Y Price Target
$23.75Price Target Upside403.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsVERITAC-2 trial indicates positive efficacy in ESR1m patients with improved benefit over elacestrant.
Drug ToleranceVepdegestrant overall was well tolerated with no major increases in adverse events.
Regulatory AlignmentOlema aligns with the FDA on 90 mg QD dose for palazestrant Phase 3 trials, which could lead to lower rates of GI toxicities while maintaining efficacy.
Bears Say
Feasibility ConcernsThe discussant at the session raised concerns about feasibility given consistent need for testing to evaluate ESR1m.
Financial RequirementsFinancing requirements for the business assume a cash runway into 2027 and ~$400M additional financing needed through 2040.
Trial ResultsThere was no benefit in the ITT population, with a median PFS of 3.7 months vs 3.6 months.
Olema Pharmaceuticals News
OLMA FAQ
What was Olema Pharmaceuticals’s price range in the past 12 months?
Olema Pharmaceuticals lowest stock price was $2.86 and its highest was $13.93 in the past 12 months.
What is Olema Pharmaceuticals’s market cap?
Olema Pharmaceuticals’s market cap is $367.42M.
When is Olema Pharmaceuticals’s upcoming earnings report date?
Olema Pharmaceuticals’s upcoming earnings report date is Aug 12, 2025 which is in 4 days.
How were Olema Pharmaceuticals’s earnings last quarter?
Olema Pharmaceuticals released its earnings results on May 13, 2025. The company reported -$0.36 earnings per share for the quarter, beating the consensus estimate of -$0.485 by $0.125.
Is Olema Pharmaceuticals overvalued?
According to Wall Street analysts Olema Pharmaceuticals’s price is currently Undervalued.
Does Olema Pharmaceuticals pay dividends?
Olema Pharmaceuticals does not currently pay dividends.
What is Olema Pharmaceuticals’s EPS estimate?
Olema Pharmaceuticals’s EPS estimate is -0.42.
How many shares outstanding does Olema Pharmaceuticals have?
Olema Pharmaceuticals has 68,421,280 shares outstanding.
What happened to Olema Pharmaceuticals’s price movement after its last earnings report?
Olema Pharmaceuticals reported an EPS of -$0.36 in its last earnings report, beating expectations of -$0.485. Following the earnings report the stock price went down -3.846%.
Which hedge fund is a major shareholder of Olema Pharmaceuticals?
Currently, no hedge funds are holding shares in OLMA
Olema Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.75 (403.18% Upside)
$23.75 (403.18% Upside)
Blogger Sentiment
Bullish
OLMA Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 97.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 6.8%
Last 30 Days ▼ 6.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-64.27%
12-Months-Change
Fundamentals
Return on Equity
-41.59%
Trailing 12-Months
Asset Growth
55.35%
Trailing 12-Months
Company Description
Olema Pharmaceuticals
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
OLMA Stock 12 Month Forecast
Average Price Target
$23.75
▲(403.18% Upside)
Technical Analysis
aTyr Pharma
―
Taysha Gene Therapies
―
Monte Rosa Therapeutics
―
2seventy bio
―
Septerna, Inc.
―
Ownership Overview
28.29% Insiders
8.40% Mutual Funds
<0.01% Other Institutional Investors
53.73% Public Companies and
Individual Investors